A Note on ERA Testing: High Cost, Uncertain Benefit
Key Takeaways
The ERA test claims to find a personalized window of implantation. However, large randomized trials (JAMA 2022) show it does not increase live birth rates. In recurrent transfer failure, embryo quality and uterine cavity evaluation take priority.
Key evidence: Doyle et al. — JAMA 2022 randomised trial (PMID 35710597) NICE NG257 — Endometrial Receptivity Testing (2026) ESHRE Good Practice Recommendations on RIF (2023)
Recently, a patient visited my clinic carrying a quote from another center. After two unsuccessful embryo transfers, she had been recommended an ERA test — involving biopsy fees, extra hormone regimens, and a delayed transfer cycle.
Her eyes carried one question: “Doctor, will this test bring me my baby?” I appreciated the question because it was honest. My answer had to be equally honest.
What Does Scientific Evidence Say?
The Endometrial Receptivity Analysis (ERA) test hypothesizes that mapping gene expression in the uterine lining can identify a personalized “window of implantation” (WOI). The concept is elegant. The problem is that clinical evidence supporting its effectiveness has failed to materialize.
- JAMA Randomized Controlled Trial (Doyle et al., 2022): Directly comparing personalized transfer timing via ERA against standard transfer timing found no significant improvement in live birth rates.
- Hum Reprod Re-Analysis (Richter & Richter, 2023): Highlighted that personalized timing based on ERA failed to reliably predict receptivity and could even reduce success in certain patient subgroups.
- NICE (2026) & ESHRE Add-ons Guidance: International regulatory and professional guidelines classify endometrial receptivity testing as lacking sufficient evidence for routine clinical use.
What Questions Should We Ask First?
When a patient experiences repeated transfer failures, my immediate clinical reflex is not to order an ERA test. In recurrent implantation failure, the true underlying cause is far more frequently found elsewhere:
1. Embryo Quality
Was the embryo cultured to the blastocyst stage? If genetic screening (PGT-A) was performed, was it conducted for a valid indication in a verified laboratory? Embryo developmental potential is the primary determinant of success.
2. Uterine Cavity Environment
Before molecular testing, visible anatomical and inflammatory factors must be thoroughly evaluated: hydrosalpinx (fluid-filled Fallopian tube), polyps, submucosal fibroids, intrauterine adhesions, or chronic endometritis. These can be detected and treated at a fraction of the cost of complex molecular panels.
3. Endometrial Preparation & Transfer Technique
Suboptimal hormone dosage, incorrect progesterone timing, a difficult transfer, or catheter displacement can compromise a cycle — issues no molecular biopsy can compensate for.
An Ethical Reflection — Refusing Silent Compliance
Over the past decade, a lucrative “add-on economy” has grown in reproductive medicine. Time-lapse imaging, embryo glue, intralipid infusions, stem cell infusions, and ERA testing share a common pattern: hope is marketed to patients, additional revenue is generated for clinics, while conclusive scientific proof remains waiting at the door.
This criticism is not directed at individual colleagues or clinics; it is a systemic reflection. Commercial pressure encourages both doctors and patients to ask: “Can we do one more thing?”
Yet good medicine often consists of having the discipline to refrain from performing an unproven test.
When Might ERA Be Considered?
I do not say “never”; I say “not routine.”
In a patient who has experienced 3 or more failed transfers of high-grade blastocysts, where embryo quality is verified, uterine pathology is excluded, endometrial preparation is optimized, and transfer technique is flawless — and who understands the limitations and wishes to explore experimental options — ERA may be discussed as an option on the table.
This is a narrow candidate profile. “Two transfers didn’t work, let me get an ERA test” does not fit this profile.
Conclusion
Returning to my patient’s question: “Will this test bring me my baby?” My answer was: “Current evidence shows it does not. Let us evaluate embryo quality, cavity anatomy, and transfer protocol first.”
We established a clear diagnostic plan. The ERA test was put aside. For the first time, she had a plan designed specifically for her biology, not sold to her anxiety.
Sources
- Doyle N, et al. Effect of Timing by Endometrial Receptivity Testing vs Standard Timing of Frozen Embryo Transfer on Live Birth…. JAMA. 2022;328(21):2117-2125.
- Richter KS, Richter ML. Personalized embryo transfer reduces success rates because endometrial receptivity analysis fails to accurately identify the window of implantation. Human Reproduction. 2023;38(6):1001-1007.
- NICE. Fertility problems: assessment and treatment (NG257). 2026. Recommendation 1.41.1.
- ESHRE Add-ons Working Group. Good Practice Recommendations on Add-ons in Reproductive Medicine. Human Reproduction Open. 2023.
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.